Kezar Life Sciences, Inc. Contracts & Agreements
44 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (3)
- Human Resources (22)
- Intellectual Property (2)
- Real Estate (2)
- Uncategorized (5)
- Rights Agreement, dated as of October 17, 2024 between Kezar Life Sciences, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as... (Filed With SEC on October 17, 2024)
- Amendment No. 1 to Collaboration and License Agreement by and between the Company and Everest Medicines II (HK) Limited, dated as of July 2, 2024 (Filed With SEC on August 13, 2024)
- Description of the Companys Securities (Filed With SEC on March 14, 2024)
- Non-Employee Director Compensation Policy (Filed With SEC on March 14, 2024)
- Executive Employment Agreement, between the Company and Christopher J. Kirk, Ph.D., dated as of November 7, 2023 (Filed With SEC on November 13, 2023)
- Separation and Consulting Agreement, between the Company and John Fowler, dated October 3, 2023 (Filed With SEC on November 13, 2023)
- Separation Agreement, between the Company and Noreen Henig, M.D., dated October 23, 2023 (Filed With SEC on November 13, 2023)
- Collaboration and License Agreement, by and between the Company and Everest Medicines II (HK) Limited, dated as of September 20, 2023 (Filed With SEC on November 13, 2023)
- Advisor Agreement between the Company and Christopher Kirk, Ph.D., dated April 22, 2023 (Filed With SEC on August 10, 2023)
- Executive Employment Agreement between the Company and Nick Mordwinkin, Ph.D., dated July 11, 2022 (Filed With SEC on November 10, 2022)
- 2022 Inducement Plan (Filed With SEC on August 11, 2022)
- Forms of Stock Option Grant Notice and Option Agreement under the 2022 Inducement Plan (Filed With SEC on August 11, 2022)
- Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under 2018 Equity Incentive Plan (Filed With SEC on March 17, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on March 17, 2022)
- Loan and Security Agreement, dated as of November 4, 2021, by and between the Company and Oxford Finance LLC (Filed With SEC on March 17, 2022)
- Sales Agreement dated as of November 19, 2021, between the Company and Cowen and Company, LLC (Filed With SEC on November 19, 2021)
- Non-Employee Director Compensation Plan (Filed With SEC on March 11, 2021)
- Underwriting Agreement, dated June 8, 2020, by and among the Company, Jefferies LLC, Cowen and Company, LLC and William Blair & Company L.L.C (Filed With SEC on June 10, 2020)
- Executive Employment Agreement, between the Company and Noreen Henig, M.D., dated April 25, 2020 (Filed With SEC on May 7, 2020)
- Executive Employment Agreement, between the Company and Vassiliki Economides, dated January 14, 2020 (Filed With SEC on May 7, 2020)
- Amended and Restated Executive Employment Agreement between the Company and Marc L. Belsky, dated January 14, 2020 (Filed With SEC on March 12, 2020)
- Non-Employee Director Compensation Plan (Filed With SEC on March 12, 2020)
- Description of the Companys Securities (Filed With SEC on March 12, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on February 3, 2020)
- Underwriting Agreement, dated January 31, 2020, by and among the Company, Cowen and Company, LLC, Wells Fargo Securities, LLC and William Blair & Company L.L.C (Filed With SEC on February 3, 2020)
- Transition Services, Separation and General Release Agreement, between the Company and Niti Goel, M.D., dated August 6, 2019 (Filed With SEC on November 7, 2019)
- Amended and Restated Executive Employment Agreement between the Company and Niti Goel, dated June 8, 2018 (Filed With SEC on May 7, 2019)
- Confirmation of Lease Terms between the Company and AP3-SF1 4000 Shoreline, LLC, effective as of March 1, 2018 (Filed With SEC on March 26, 2019)
- Form of Underwriting Agreement (Filed With SEC on June 8, 2018)
- Form of Common Stock Certificate of the Registrant (Filed With SEC on June 8, 2018)
- Amended and Restated Executive Employment Agreement between the Registrant and John Fowler, dated June 7, 2018 (Filed With SEC on June 8, 2018)
- Amended and Restated Executive Employment Agreement between the Registrant and Christopher J. Kirk, dated June 7, 2018 (Filed With SEC on June 8, 2018)
- Exclusive License Agreement by and between the Registrant and Onyx Therapeutics, Inc., dated June 11, 2015 (Filed With SEC on June 8, 2018)
- 2018 Equity Incentive Plan (Filed With SEC on May 24, 2018)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 26, 2017 (Filed With SEC on May 24, 2018)
- Form of Indemnity Agreement by and between the Registrant and its directors and officers (Filed With SEC on May 24, 2018)
- Forms of Option Grant Notice and Option Agreement under 2018 Equity Incentive Plan (Filed With SEC on May 24, 2018)
- Lease between the Registrant and AP3-SF1 4000 Shoreline, LLC, dated August 16, 2017 (Filed With SEC on May 24, 2018)
- Exclusive License Agreement by and between the Registrant and Onyx Therapeutics, Inc., dated June 11, 2015 (Filed With SEC on May 24, 2018)
- 2018 Employee Stock Purchase Plan (Filed With SEC on May 24, 2018)
- Form of Stock Option AgreementEarly Exercise under the 2015 Equity Incentive Plan (Filed With SEC on May 24, 2018)
- Form of Stock Option Agreement under the 2015 Equity Incentive Plan (Filed With SEC on May 24, 2018)
- 2015 Equity Incentive Plan, as amended (Filed With SEC on May 24, 2018)
- Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under 2018 Equity Incentive Plan (Filed With SEC on May 24, 2018)
